Study of Intravenous Tranexamic Acid for Adults with Spontaneous Intracerebral Hemorrhage Within 4.5 Hours of Stroke Symptoms
Led by Christian Medical College and Hospital, Ludhiana, India · Updated on 2026-01-22
3400
Participants Needed
48
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether Tranexamic Acid can improve outcomes in adults who have a spontaneous intracerebral haemorrhage, a type of stroke caused by bleeding within the brain. This trial focuses on patients who arrive within 4.5 hours after stroke symptoms begin. The study is important because this condition has a high risk of death and disability, and early treatment with haemostatic drugs like Tranexamic Acid could potentially reduce bleeding and improve recovery. The trial is conducted across multiple centers in India and aims to enroll 3400 patients.
Participants will be randomly assigned to one of two groups. One group receives 2 grams of Tranexamic Acid given intravenously over 45 minutes, along with intensive blood pressure control to maintain systolic pressure below 140 mmHg for seven days. The other group receives standard care with the same blood pressure management protocol. Both groups will have CT brain scans after 24 hours to check for changes in bleeding. Blood pressure is closely monitored every 15 minutes for the first hour and then hourly for six hours.
During the study, patients will be assessed using neurological scores on day 7 and their quality of life and functional status will be measured on day 90. Researchers will monitor death rates within 30 days, changes in haematoma size, neurological impairments, and overall recovery. The study includes regular neurological evaluations and brain imaging as needed. Participation lasts at least 90 days to evaluate outcomes and safety.
CONDITIONS
Brief Title
Indian Trial of Tranexamic Acid in Spontaneous Intracerebral Haemorrhage
Research Team
J
Jeyaraj D Pandian, MD DM
A
Atul Phillips, MD FNB
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Christian Medical College and Hospital, Ludhiana, India
Lead Sponsor
Indian Council of Medical Research
Collaborating Sponsor
Who Can Participate
Age: 18Years - 99Years
All Genders
Eligibility Criteria
You may qualify if you...
Adult patients aged more than 18 years
Presenting with non-traumatic intracerebral haemorrhage
Onset of stroke symptoms within 4.5 hours
Confirmed diagnosis by CT scan
Able to receive treatment and follow-up for 90 days
You will not qualify if you...
Intracerebral haemorrhage caused by anticoagulation, thrombolysis, or structural abnormalities like arteriovenous malformation, aneurysm, tumor, or venous thrombosis
Known hereditary coagulation disorders
Contraindication to Tranexamic Acid
Participation in another clinical trial
Pre-stroke life expectancy less than 3 months
Glasgow Coma Scale score of 5 or less
Intracerebral haemorrhage due to trauma
Women who are pregnant, breastfeeding, or of childbearing potential
Inability to follow up for 90 days due to geographic or other reasons
Concurrent or planned treatment with other hemostatic agents
Intracerebral haemorrhage volume greater than 60 mL measured by ABC/2 method
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 7 days
Participants receive intravenous Tranexamic Acid over 45 minutes and intensive blood pressure control for 7 days, or standard care with intensive blood pressure control for 7 days.
Continuous monitoring during the first 7 days with frequent blood pressure checks every 15 minutes for the first hour and hourly for the next 6 hours
Follow-up
Duration - Up to 90 days
Participants are assessed for neurological status on day 7 and functional outcomes including quality of life on day 90.
Visits on day 7 and day 90 (in-person or remote assessments)
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
The spot sign and tranexamic acid on preventing ICH growth--AUStralasia Trial (STOP-AUST): protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial.
Atte Meretoja, Leonid Churilov, Bruce C V Campbell...